BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.64 --0%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
ELWT, CAAP, RNW, More
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
ELWT, CAAP, RNW, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.51 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
- XP Inc. (XP) Tops Q2 EPS by 8c
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $88 at Piper Sandler
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
